Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results Feb 24, 2015 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2014 on Tuesday, February 24, 2015, After Close of U.S.-Based Financial Markets Feb 17, 2015 Baxter Presents Additional Data From Pivotal Study Of BAX 855, Extended Half-life Investigational Recombinant FVIII Based On ADVATE For Hemophilia A Feb 11, 2015 Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA Jan 06, 2015 Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer Dec 11, 2014 MOVENTIG® Approved In The European Union For Opioid-Induced Constipation Dec 09, 2014 Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A Dec 01, 2014 Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model Nov 20, 2014 Nektar Therapeutics Reports Financial Results for the Third Quarter of 2014 Nov 06, 2014 Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets Oct 30, 2014 Pagination First page « first Previous page ‹ previous … Page 24 Page 25 Page 26 Page 27 Current page 28 Page 29 Page 30 Page 31 Page 32 … Next page next › Last page last »